Vivek Ramaswamy discloses 6.8% Roivant Sciences (ROIV) stake

Rhea-AI Filing Summary

Vivek Ramaswamy reported a 6.8% beneficial ownership stake in Roivant Sciences Ltd. common shares as of the event dated 12/31/2025. He is deemed to beneficially own 48,428,792 common shares, made up of 33,709,547 restricted share awards and 14,719,245 common shares underlying options.

The ownership percentage is calculated using 710,210,860 common shares, based on 695,491,615 shares outstanding as of November 3, 2025 and options expected to vest and settle within 60 days of December 31, 2025. The reported holdings exclude 13,357,857 shares held solely by his spouse.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

Roivant Sciences Ltd.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

G76279101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G76279101

1

Names of Reporting Persons

Ramaswamy Vivek

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 48,428,792.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 48,428,792.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

48,428,792.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: All calculations of percentage ownership herein are based on an aggregate of 710,210,860 common shares issued and outstanding as of November 3, 2025, based on (i) 695,491,615 common shares issued and outstanding as of November 3, 2025, as disclosed by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2025, as filed with the Securities and Exchange Commission on November 10, 2025, and (ii) 14,719,245 common shares underlying Options held by Mr. Ramaswamy that are subject to vesting and settlement within 60 days of December 31, 2025, and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i). Ownership totals disclosed do not include 13,357,857 shares held solely by Mr. Ramaswamy's spouse.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Roivant Sciences Ltd.
(b)	Address of issuer's principal executive offices: 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM, SW1H 0DB
Item 2.
(a)	Name of person filing: This Amendment to Schedule 13G {the "Amendment") is being filed by Vivek Ramaswamy (the "Reporting Person").
(b)	Address or principal business office or, if none, residence: c/o Steve Roberts, Lex Politica PLLC, 611 Pennsylvania Ave., SE, Ste 353, Washington, DC 20003
(c)	Citizenship: See row 4 of the cover page to this Amendment.
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: G76279101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 48,428,792 common shares, consisting of (i) 33,709,547 RSAs covering common shares and (ii) 14,719,245 common shares underlying Options.
(b)	Percent of class: 6.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 48,428,792 common shares, consisting of (i) 33,709,547 RSAs covering common shares and (ii) 14,719,245 common shares underlying Options.
	(ii) Shared power to vote or to direct the vote: N/A
	(iii) Sole power to dispose or to direct the disposition of: 48,428,792 common shares, consisting of (i) 33,709,547 RSAs covering common shares and (ii) 14,719,245 common shares underlying Options.
	(iv) Shared power to dispose or to direct the disposition of: N/A
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Ramaswamy Vivek

Signature:	/s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy
Name/Title:	Vivek Ramaswamy
Date:	02/13/2026

FAQ

What stake in Roivant Sciences Ltd. (ROIV) does Vivek Ramaswamy report in this Schedule 13G/A?

Vivek Ramaswamy reports beneficial ownership of 48,428,792 Roivant common shares, equal to 6.8% of the class. This figure includes restricted share awards and options deemed outstanding under SEC rules for calculation of beneficial ownership.

How is Vivek Ramaswamy’s 6.8% ownership in Roivant Sciences (ROIV) calculated?

The 6.8% figure is based on 710,210,860 common shares. This total reflects 695,491,615 shares outstanding as of November 3, 2025, plus 14,719,245 common shares underlying options that may vest and settle within 60 days of December 31, 2025.

What types of Roivant shares make up Vivek Ramaswamy’s reported holdings?

His reported 48,428,792 Roivant common shares consist of 33,709,547 restricted share awards (RSAs) and 14,719,245 common shares underlying options. Both RSAs and the exercisable option shares are treated as beneficially owned under the SEC’s beneficial ownership rules.

Does the Roivant Sciences (ROIV) filing include shares held by Vivek Ramaswamy’s spouse?

The disclosure states that ownership totals do not include 13,357,857 shares held solely by Mr. Ramaswamy’s spouse. These shares are explicitly excluded from the reported 48,428,792 common shares deemed beneficially owned by Mr. Ramaswamy in this amendment.

What is the relevant date for Vivek Ramaswamy’s Roivant Sciences (ROIV) Schedule 13G/A amendment?

The amendment lists 12/31/2025 as the event date requiring the filing. The ownership percentage uses outstanding share data as of November 3, 2025, combined with option shares expected to vest within 60 days of December 31, 2025.

What voting and dispositive powers does Vivek Ramaswamy report over Roivant Sciences (ROIV) shares?

He reports sole voting power over 48,428,792 common shares and sole dispositive power over the same amount. The filing indicates no shared voting power and no shared dispositive power with respect to Roivant common shares.